Interferon alpha therapy for hepatitis C: Treatment completion and response rates among patients with substance use disorders

Substance Abuse: Treatment, Prevention, and Policy

Volumn 2, Issue 1, 2007, Pages

  Huckans, Marilyn S ^a,b   Loftis, Jennifer M ^a,b   Blackwell, Aaron D ^a,d   Linke, Alex ^a   Hauser, Peter ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ADDICTION; ARTICLE; COMORBIDITY; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STATISTICS; TREATMENT OUTCOME; UNITED STATES; VETERAN; VIRUS LOAD;

ANTIVIRAL AGENTS; COMORBIDITY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES; VETERANS; VIRAL LOAD;

EID: 34248401506     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-2-4     Document Type: Article

References (38)

1. Huckans MS Blackwell AD Harms TA Hauser P Hepatitis C disease management patterns in high-risk populations: Testing, infection, and treatment rates among patients with serious mental illness and substance use disorders Psychiatric Services 2006 57 3 403-6 10.1176/appi.ps.57.3.403 16525001
2. Osher FC Goldberg RW McNary SW Swartz MS Essock SM Butterfield MI Rosenberg SD Substance abuse and the transmission of hepatitis C among persons with severe mental illness Psychiatr Serv 2003 54 842-847 10.1176/appi.ps.54.6.842 12773598
3. el-Serag HB Kunik M Richardson P Rabeneck L Psychiatric disorders among veterans with hepatitis C infection Gastroenterology 2002 123 476-482 10.1053/gast.2002.34750 12145801
4. Dinwiddie SH Shicker L Newman T Prevalence of hepatitis C among psychiatric patients in the public sector Am J Psychiatry 2003 160 172-174 10.1176/appi.ajp.160.1.172 12505819
5. Patrick DM Buxton JA Bigham M Mathias RG Public health and hepatitis C Can J Public Health 2000 91 Suppl 1 S18-21, S19-23 11059125
6. Tortu S Neaigus A McMahon J Hagen D Hepatitis C among noninjecting drug users: A report Subst Use Misuse 2001 36 523-534 10.1081/JA-100102640 11346280
7. Fried MW Shiffman ML Reddy KR Smith C Marinos G Goncales FL Jr. Haussinger D Diago M Carosi G Dhumeaux D Craxi A Lin A Hoffman J Yu J Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 2002 347 975-982 10.1056/NEJMoa020047 12324553
8. Manns MP McHutchison JG Gordon SC Rustgi VK Shiffman M Reindollar R Goodman ZD Koury K Ling M Albrecht JK Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001 358 958-965 10.1016/S0140-6736(01)06102-5 11583749
9. Loftis JM Hauser P The phenomenology and treatment of interferon-induced depression J Affect Disord 2004 82 175-190 10.1016/j.jad.2004.04.002 15488246
10. Malaguarnera M Laurino A Di Fazio I Pistone G Castorina M Guccione N Rampello L Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C J Interferon Cytokine Res 2001 21 273-278 10.1089/ 107999001300177457 11429157
11. Dieperink E Ho SB Thuras P Willenbring ML A Prospective Study of Neuropsychiatric Symptoms Associated With Interferon-alpha-2b and Ribavirin Therapy for Patients With Chronic Hepatitis C Psychosomatics 2003 44 104-112 10.1176/appi.psy.44.2.104 12618532
12. Fried MW Side effects of therapy of hepatitis C and their management Hepatology 2002 36 S237-44 10.1002/hep.1840360730 12407599
13. Hauser P Khosla J Aurora H Laurin J Kling MA Hill J Gulati M Thornton AJ Schultz RL Valentine AD Meyers CA Howell CD A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C Mol Psychiatry 2002 7 942-947 10.1038/sj.mp.4001119 12399946
14. Ho SB Nguyen H Tetrick LL Opitz GA Basara ML Dieperink E Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population Am J Gastroenterol 2001 96 157-164 11197246
15. Edlin BR Kresina TF Raymond DB Carden MR Gourevitch MN Rich JD Cheever LW Cargill VA Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users Clin Infect Dis 2005 40 Suppl 5 S276-85 1510897 15768335 10.1086/427441
16. Stephenson J Former addicts face barriers to treatment for HCV Jama 2001 285 1003-1005 10.1001/jama.285.8.1003 11209154
17. Schaefer M Heinz A Backmund M Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction 2004 99 1167-1175 10.1111/j.1360-0443.2004.00821.x 15317637
18. Muir AJ Provenzale D A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection J Clin Gastroenterol 2002 34 268-271 10.1097/00004836-200203000-00015 11873110
19. Cawthorne CH Rudat KR Burton MS Brown KE Luxon BA Janney CG Fimmel CJ Limited success of HCV antiviral therapy in United States veterans Am J Gastroenterol 2002 97 149-155 10.1111/j.1572-0241.2002.05439.x 11808940
20. Hatem C Minello A Bresson-Hadni S Jooste V Evrard P Obert B Lepage C Bonithon-Kopp C Faivre J Monnet E Miguet JP Hillon P Is the management of hepatitis C patients appropriate? A population-based study Aliment Pharmacol Ther 2005 21 1007-1015 10.1111/j.1365-2036.2005.02393.x 15813837
21. Sylvestre DL Treating hepatitis C virus infection in active substance users Clin Infect Dis 2005 40 Suppl 5 S321-4 10.1086/427447 15768341
22. Sylvestre DL Treating hepatitis C in methadone maintenance patients: An interim analysis Drug Alcohol Depend 2002 67 117-123 10.1016/ S0376-8716(02)00010-8 12095661
23. Dalgard O Bjoro K Hellum K Myrvang B Skaug K Gutigard B Bell H Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up Eur Addict Res 2002 8 45-49 10.1159/000049487 11818693
24. Backmund M Meyer K Von Zielonka M Eichenlaub D Treatment of hepatitis C infection in injection drug users Hepatology 2001 34 188-193 10.1053/ jhep.2001.25882 11431750
25. Robaeys G Buntinx F Treatment of hepatitis C viral infections in substance abusers Acta Gastroenterol Belg 2005 68 55-67 15832589
26. Fireman M Hepatitis C treatment and substance use disorders Psychiatric Annals 2003 33 1-7
27. Loguercio C Di Pierro M Di Marino MP Federico A Disalvo D Crafa E Tuccillo C Baldi F del VecchioBlanco C Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects Alcohol Alcohol 2000 35 296-301 10869251
28. Ohnishi K Matsuo S Matsutani K Itahashi M Kakihara K Suzuki K Ito S Fujiwara K Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers Am J Gastroenterol 1996 91 1374-1379 8677998
29. Okazaki T Yoshihara H Suzuki K Yamada Y Tsujimura T Kawano K Abe H Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers Scand J Gastroenterol 1994 29 1039-1043 7871371
30. Tabone M Sidoli L Laudi C Pellegrino S Rocca G Della Monica P Fracchia M Galatola G Molinaro GC Arico S Pera A Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy J Viral Hepat 2002 9 288-294 10.1046/ j.1365-2893.2002.00360.x 12081606
31. Anand BS Currie S Dieperink E Bini EJ Shen H Ho SB Wright T Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study Gastroenterology 2006 130 1607-1616 10.1053/j.gastro.2006.02.023 16697724
32. De Bie J Robaeys G Buntinx F Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice Acta Gastroenterol Belg 2005 68 68-80 15832590
33. Davis GL Rodrigue JR Treatment of chronic hepatitis C in active drug users N Engl J Med 2001 345 215-217 10.1056/NEJM200107193450312 11463020
34. Huber M Weber R Oppliger R Vernazza P Schmid P Schonbucher P Bertisch B Meili D Renner EL Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: An open-label randomized multicenter trial Infection 2005 33 25-29 10.1007/ s15010-005-4043-2 15750756
35. Edlin BR Seal KH Lorvick J Kral AH Ciccarone DH Moore LD Lo B Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001 345 211-215 1510901 11463019 10.1056/ NEJM200107193450311
36. Strader DB Wright T Thomas DL Seeff LB Diagnosis, management, and treatment of hepatitis C Hepatology 2004 39 1147-1171 10.1002/hep.20119 15057920
37. NIH Consensus Development Conference Statement: Management of hepatitis C Hepatology 2002 36 S3-20 12407572
38. VA VA Treatment Recommendations for Patients with Chronic Hepatitis C, Version 5.0 Federal Practitioner 2003 20 1-32